# Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00462852** · PHASE2 · COMPLETED · sponsor: **Hull University Teaching Hospitals NHS Trust** · enrollment: 120 (estimated)

## Conditions studied

- Pancreatic Cancer
- Thromboembolism

## Interventions

- **DRUG:** dalteparin
- **DRUG:** gemcitabine hydrochloride
- **OTHER:** diagnostic laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00462852
- **Lead sponsor:** Hull University Teaching Hospitals NHS Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2011-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462852, "Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00462852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*